sutimlimab-jome

CHEBI:CHEBI_749478

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2591425
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
route
INTRAVENOUS
active_ingredient_strength
50 mg/mL
dosage_form
INJECTION, SOLUTION, CONCENTRATE
marketing_category
BLA
marketing_start_date
20220204
package_marketing_start_date
20220204
labeler_name
Bioverativ Therapeutics Inc.
manufacturer_name
Bioverativ Therapeutics Inc.
generic_name
sutimlimab-jome
brand_name
Enjaymo
brand_name_base
Enjaymo
product_ndc
80203-347
application_number
BLA761164
spl_id
486710f9-4172-4fe4-b05f-64413cc8fbfc
active_ingredient_name
SUTIMLIMAB
package_ndc
80203-347-01
package_description
1 VIAL, SINGLE-DOSE in 1 CARTON (80203-347-01) / 22 mL in 1 VIAL, SINGLE-DOSE
unii
GNWE7KJ995
spl_set_id
281cf1d4-6296-4416-858e-9bff46d01b71
nui
N0000193990
pharm_class_epc
Classical Complement Pathway Inhibitor [EPC]
pharm_class
Classical Complement Pathway Inhibitors [MoA]
pharm_class_moa
Classical Complement Pathway Inhibitors [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class